Translational Research Training in Hematology Hall of Fame

Patient organizations

EHA greatly values the collaboration with patient organizations in a growing number of areas, from joint advocacy and a strong presence at the EHA Annual Congress – with a prominent place for the EHA-Patient Joint Symposium on policy and regulatory…

SWG Educational Activities

Past EHA (HOPE) Asia 2021 meeting 10-11 September 2021, Virutal

Speakers
Laane - Systematic review of literature on multiple myeloma EHA evidence-based “Guidelines for the use of patient-reported outcomes in adult patients with hematological malignancies” in progress - Systematic review of literature…

Dutch scientists propose algorithm to keep drugs affordable and accessible

May 8, 2018, The Hague - An important contribution to the debate about the affordability and accessibility of innovative medicines appeared in Nature Reviews, proposing the adoption of a novel model of price setting with examples of implementation.

Code of Conduct

The guidelines below govern the publication of, and commentary on the EHA Hematology Hub. Please read through them before participating. 1. Abide by the rules that normally apply.

The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders

The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders was held on February 16-18 in Lucknow, India, and chaired by Dr AK Tripathi (King George’s Medical University, Lucknow, India) and Prof G Gaidano (University of Eastern Piedmont, Novara,…

EHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation

To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.